Roivant Sciences Ltd. Reports 2026 AGM Voting Results

What Happened
Roivant Sciences Ltd. (ROIV) filed an 8‑K on September 18, 2026 reporting the results of its 2026 Annual General Meeting held on September 16, 2026. Shareholders re‑elected two Class II directors, ratified Ernst & Young LLP (EY) as independent auditor for the fiscal year ending March 31, 2027, and approved the company’s named executive officer compensation on a non‑binding advisory basis. A quorum was present: 652,143,869 of 722,406,273 shares entitled to vote (≈90.3%).

Key Details

• Meeting date and filing: Annual General Meeting on Sept. 16, 2026; 8‑K filed Sept. 18, 2026; Proxy Statement previously filed July 29, 2026.
• Director elections (Class II, term through the AGM after fiscal year ending Mar. 31, 2029):
  • Daniel Gold: For 375,791,264; Withheld 210,203,958; Broker non‑vote 66,148,647 (For ≈64.13% of votes cast).
  • Meghan FitzGerald: For 422,428,908; Withheld 163,566,314; Broker non‑vote 66,148,647 (For ≈72.07% of votes cast).
• Auditor ratification: Ernst & Young LLP ratified as independent registered public accounting firm for fiscal year ending Mar. 31, 2027 — For 651,315,490; Against 731,364; Abstain 97,015.
• Say‑on‑pay (non‑binding advisory vote on executive compensation): Approved — For 316,702,500; Against 269,062,122; Abstain 230,600 (For ≈54.05% of votes cast); broker non‑votes 66,148,647.

Why It Matters

• Board continuity and governance: Re‑election of Class II directors preserves current board composition through the 2029 cycle, which can affect oversight and strategic continuity.
• Auditor: Ratification of EY confirms the company’s external audit provider for the coming fiscal year, an important factor for financial reporting integrity.
• Executive pay: The say‑on‑pay passed but by a modest margin (~54% of votes cast), indicating a meaningful minority of shareholders opposed the disclosed executive compensation. Investors may track this as a governance signal or watch for future engagement/changes.